1188477-11-3

Basic information

• Product Name: Tert-Butyl5-Bromopyridin-2-yl(methyl)carbamate
• Synonyms: Tert-Butyl5-Bromopyridin-2-yl(methyl)carbamate;Carbamic acid, N-[(5-bromo-2-pyridinyl)methyl]-, 1,1-dimethylethyl ester
• CAS NO: 1188477-11-3
• Molecular Formula: C₁₁H₁₅BrN₂O₂
• Molecular Weight: 287.153
• Mol File: 1188477-11-3.mol

Chemical Properties

• Boiling Point: 372.4±32.0 °C(Predicted)
• Appearance: /
• Density: 1.367±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.14±0.46(Predicted)
• CAS DataBase Reference: Tert-Butyl5-Bromopyridin-2-yl(methyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: Tert-Butyl5-Bromopyridin-2-yl(methyl)carbamate(1188477-11-3)
• EPA Substance Registry System: Tert-Butyl5-Bromopyridin-2-yl(methyl)carbamate(1188477-11-3)

Safety Data

• Hazardous Substances Data: 1188477-11-3(Hazardous Substances Data)

Usage

Uses

Since the provided materials do not specify any particular applications for Tert-Butyl5-Bromopyridin-2-yl(methyl)carbamate, it is not possible to list its uses based on the given information. However, given its classification as a chemical compound within the field of organic chemistry, it is likely that this compound may have potential applications in various industries, such as pharmaceuticals, materials science, or agrochemicals, depending on its specific properties and reactivity. Further research and development would be required to explore and confirm its potential uses in these or other industries.

Upstream product

• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 4248-19-5 tert-butyl carbazate 
• 173999-23-0 C-(5-bromo-pyridin-2-yl)-methylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 97483-77-7 2-Cyano-5-bromopyridine 

Downstream Products

• 173999-23-0 C-(5-bromo-pyridin-2-yl)-methylamine 
• 928648-90-2 (Z)-(5-(2-cyclohexylvinyl)pyridin-2-yl)methanamine 
• 1454904-80-3 2,2-dichloro-N-{(1S,2R)-1-fluoromethyl-2-hydroxy-2-[4-(6-ureidomethylpyridin-3-yl)phenyl]ethyl}acetamide 
• 1454904-54-1 2,2-dichloro-N-((1S,2R)-1-fluoromethyl-2-hydroxy-2-{4-[6-(isopropylaminomethyl)pyridin-3-yl]phenyl}ethyl)acetamide 
• 1454907-21-1 (4S,5R)-4-fluoromethyl-5-{4-[6-(isopropylaminomethyl)pyridin-3-yl]phenyl}-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester 
• 1454904-20-1 2,2-difluoro-N-((1R,2S)-3-fluoro-1-hydroxy-1-(4-(6-((2-methylpropylsulfonamido)methyl)pyridin-3-yl)phenyl)propan-2-yl)acetamide 
• 1454906-89-8 1-((4S,5R)-5-(4-(6-(aminomethyl)pyridin-3-yl)phenyl)-4-(fluoromethyl)-2,2-dimethyloxazolidin-3-yl)-2,2-difluoroethanone 

Relevant articles and documents

INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF

Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.

FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compound-linker constructs and antibody-drug-conjugates of compounds of formula (I) that are useful as modulators of STING (Stimulator of Interferon Genes).

Z-Selective Synthesis of Vinyl Boronates through Fe-Catalyzed Alkyl Radical Addition

Z-Selective synthesis of vinyl boronates is challenging. This work describes Fe-catalyzed addition of alkyl radicals, formed by the corresponding alkyl halides, to ethynyl ethynylboronic acid pinacol ester that gives rise to Z-vinyl boronates in high ster

Z-Selective Synthesis of Vinyl Boronates through Fe-Catalyzed Alkyl Radical Addition

Z-Selective synthesis of vinyl boronates is challenging. This work describes Fe-catalyzed addition of alkyl radicals, formed by the corresponding alkyl halides, to ethynyl ethynylboronic acid pinacol ester that gives rise to Z-vinyl boronates in high ster

AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described herein.

1,2,3-BENZOTRIAZOLE DERIVATIVES AS ROR GAMMA T MODULATORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, G, L, R1, Rx, Ry, X1, X2, X3, X4, n, p, q and t are

Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the ‘reversed’ amide scaffold

The Wnt signaling pathway is an essential signal transduction pathway which leads to the regulation of cellular processes such as proliferation, differentiation and migration. Aberrant Wnt signaling is known to have an association with multiple cancers. Porcupine is an enzyme that catalyses the addition of palmitoleate to a serine residue in Wnt proteins, a process which is required for the secretion of Wnt proteins. Here we report the synthesis and structure–activity-relationship of the novel porcupine inhibitors based on a ‘reversed’ amide scaffold. The leading compound 53 was as potent as the clinical compound LGK974 in a cell based STF reporter gene assay. Compound 53 potently inhibited the secretion of Wnt3A, therefore was confirmed to be a porcupine inhibitor. Furthermore, compound 53 showed excellent chemical and plasma stabilities. However, the clearance of compound 53 in liver microsomal tests was moderate to high, and the solubility of compound 53 was suboptimal. Collective efforts toward further optimization of this novel tricyclic template to develop better porcupine inhibitors will be subsequently undertaken and reported in due course.

TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to substituted indole compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, adisease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS

The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.